IMUGENE LIMITED

5.41%

3.5¢

Market Cap $261.2M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

IMU Biotech

IMUGENE CHART. TA only

609 610 611

21/03/25

36K

18M

21/03/25

Last post Devildamian

36K

18M

IMU

Why IMU is a multi multi bagger

503 504 505

21/03/25

30K

15M

21/03/25

Last post Meribe

30K

15M

IMU

Anyone else frustrated with the SP with all the positive news we have received lately?

3 4 5

21/03/25

268

139K

21/03/25

Last post 1MRX

268

139K

IMU

Ann: Azer-cel Granted FDA Fast Track Designation in Blood Cancer

2 3

21/03/25

144

59K

21/03/25

Last post Ianwil

144

59K

IMU

Why IMU is NOT a MULTI Bagger is a BAGGIES company

2 3 4

21/03/25

201

89K

21/03/25

Last post Stickshift

201

89K

IMU

Media Thread

295 296 297

21/03/25

17K

8.5M

21/03/25

Last post DDD24

17K

8.5M

IMU

Ann: Imugene onCARlytics with blinatumomab SITC presentation

19/03/25

15K

19/03/25

Last post col75

15K

IMU

IMUOE are in the money

19/03/25

26K

19/03/25

Last post Footmax

26K

See All Discussions

Timeline

Azer-cel Granted FDA Fast Track Designation in Blood Cancer
19 Mar 09:02	Share

Application for quotation of securities - IMU
13 Mar 17:51	Share

S&P DJI Announces March 2025 Quarterly Rebalance
07 Mar 17:01	Share

Darren Keamy Appointed CFO and Company Secretary
04 Mar 09:01	Share

Half Yearly Report and Accounts
28 Feb 10:00	Share

Imugene Granted India Patent for Oncolytic Virotherapy CF33
27 Feb 08:59	Share

Imugene OnCARlytics Patent Allowance in China
26 Feb 08:58	Share

Change of Directors Interest Notice x 5
21 Feb 16:53	Share

Notification regarding unquoted securities - IMU
21 Feb 16:46	Share

Application for quotation of securities - IMU
21 Feb 16:45	Share

Azer-cel demonstrates two additional Complete Responses
14 Feb 08:44	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 08:50	Share

Notification of cessation of securities - IMU
29 Jan 16:58	Share

Application for quotation of securities - IMU
29 Jan 16:56	Share

Imugene Receives A$20 million for Convertible Notes Issuance
29 Jan 08:19	Share

Notification regarding unquoted securities - IMU
28 Jan 09:02	Share

Release of Shares from Voluntary Escrow
24 Jan 18:54	Share

Cleansing Notice
24 Jan 18:32	Share

Notification regarding unquoted securities - IMU
24 Jan 17:05	Share

Results of Meeting
22 Jan 13:39	Share

Imugene EGM Presentation
22 Jan 08:57	Share

Application for quotation of securities - IMU
10 Jan 16:58	Share

Imugene Receives $11.7m R&D Tax Refund
10 Jan 13:31	Share

First Australian Patient Dosed in Phase 1b azer-cel Trial
03 Jan 08:34	Share

Proposed issue of securities - IMU
24 Dec 08:38	Share

Notice of Extraordinary General Meeting/Proxy Form
23 Dec 18:25	Share

Issuance of Convertible Notes & Warrants for up to $46m
23 Dec 17:29	Share

Azer-cel Accepted for Presentation at ASTCT Tandem Meetings
20 Dec 13:20	Share

Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
19 Dec 08:54	Share

Updated Appendix 3Z
20 Nov 18:25	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.5¢		Change -0.002(5.41%)		Mkt cap ! $261.2M

Open	High	Low	Value	Volume
3.6¢	3.7¢	3.5¢	$7.659M	217.7M

Buyers (Bids)

No.	Vol.	Price($)
2	1371131	3.5¢

Sellers (Offers)

Price($)	Vol.	No.
3.6¢	19046	1

View Market Depth

No.	Vol.	Price($)
1	1000000	0.035
21	7737599	0.034
27	4378118	0.033
23	7313778	0.032
30	8312816	0.031

Price($)	Vol.	No.
0.036	19046	1
0.037	450000	2
0.038	2638255	6
0.039	1893320	11
0.040	3163297	16

Last trade - 16.10pm 21/03/2025 (20 minute delay)


Last 3.7¢		Change -0.002 ( 0.00 %)
Open	High	Low	Volume
3.6¢	3.7¢	3.5¢	18423218
Last updated 15.59pm 21/03/2025 ?

IMU (ASX) Chart

IMUGENE LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Imugene (ASX:IMU) doses first patients in VAXINIA combination study

03 Mar 2023 14:39 (AEDT)

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

10 Feb 2023 10:58 (AEDT)

Imugene (ASX:IMU) advances VAXINIA trial

02 Feb 2023 12:21 (AEDT)

Latest Articles

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b t...

Imugene kicks off Australian trial for blood cancer treatment

Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test CAR T cell therapy azer-cel

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A @complete response’ in this case is a complete disappearance of all tumours. The company is focusing o...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News